Satish K Surabhi. MD.FACC.FSCAI.RPVI

Medical Director, Cardiac Cath LabsAnMed Heart & Vascular Care

None

Evolocumab ( 2976) vs Standard Rx (1489) All CV events 0.95% vs 2.18% MACE 0.95% vs 2.1 % Death 0.14% vs 0.41%

Curves separated early

Cost Access to medicines Compliance Neurocognitive effects 0.9 % vs 0.3% Long term follow up studies

Outcome studies in various populations

Longer acting agents.. Q 6 months? Q 1yr?

Vaccine ?

Combined/ sequential/ intermittent therapy